Olympus Corporation
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Dodge & Cox Funds-Dodge & Cox International Stock Fund
|
21.4M | 0.00% | |
|
MFS Series Trust XVII-MFS International Equity Fund
|
20.4M | +25.49% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
15.7M | +0.05% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
10.0M | +2.40% | |
|
Bridge Builder Trust-Bridge Builder International Equity Fund
|
7.7M | -27.13% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
7.8M | +0.84% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
11.8K | +0.72% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥20 | +11.1% |
| 2024 | ¥18 | +12.5% |
| 2023 | ¥16 | +14.3% |
| 2022 | ¥14 | +16.7% |
| 2021 | ¥12 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥750,123M | ¥881,923M | ¥925,752M | ¥997,332M |
| Gross Profit | ¥506,700M | ¥596,849M | ¥618,432M | ¥683,697M |
| Operating Income | ¥144,696M | ¥186,118M | ¥51,745M | ¥161,996M |
| Pretax Income | ¥147,539M | ¥190,469M | ¥53,907M | ¥165,911M |
| Net Income | ¥115,742M | ¥143,432M | ¥242,566M | ¥117,855M |
| EPS | ¥90.17 | ¥113.08 | ¥199.44 | ¥102.80 |
| Operating Margin | 19.29% | 21.10% | 5.59% | 16.24% |
| Balance Sheet | ||||
| Total Assets | ¥1,357,999M | ¥1,508,701M | ¥1,534,216M | ¥1,432,826M |
| Total Equity | ¥510,168M | ¥640,085M | ¥757,186M | ¥751,733M |
| Total Liabilities | ¥847,831M | ¥868,616M | ¥777,030M | ¥681,093M |
| Cash | ¥302,572M | ¥169,329M | ¥340,933M | ¥252,532M |
| Interest-bearing Debt | ¥386,127M | ¥340,057M | ¥299,616M | ¥229,102M |
| Equity Ratio | 37.57% | 42.43% | 49.35% | 52.47% |
| D/E Ratio | 0.76 | 0.53 | 0.40 | 0.30 |
| Cash Flow | ||||
| Operating CF | ¥169,729M | ¥98,490M | ¥42,365M | ¥190,463M |
| Investing CF | -¥71,016M | -¥58,414M | ¥359,992M | -¥65,469M |
| Financing CF | -¥40,667M | -¥143,178M | -¥276,010M | -¥211,542M |
| Free CF | ¥107,958M | ¥27,867M | -¥22,259M | ¥125,254M |
| Efficiency | ||||
| ROE | 22.69% | 22.41% | 32.04% | 15.68% |
| ROA | 8.52% | 9.51% | 15.81% | 8.23% |
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,070
Rating Score: - (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.